Compare ACIW & CRNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ACIW | CRNX |
|---|---|---|
| Founded | 1975 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.5B | 3.9B |
| IPO Year | 1996 | 2018 |
| Metric | ACIW | CRNX |
|---|---|---|
| Price | $54.64 | $42.21 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 8 |
| Target Price | $62.50 | ★ $76.75 |
| AVG Volume (30 Days) | 960.8K | ★ 1.3M |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 13.09 | N/A |
| EPS | ★ 0.37 | N/A |
| Revenue | ★ $1,009,780,000.00 | $1,039,000.00 |
| Revenue This Year | $9.67 | $720.10 |
| Revenue Next Year | $7.41 | $184.67 |
| P/E Ratio | $148.46 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $38.05 | $25.83 |
| 52 Week High | $54.95 | $57.99 |
| Indicator | ACIW | CRNX |
|---|---|---|
| Relative Strength Index (RSI) | 79.63 | 71.81 |
| Support Level | $46.22 | $38.68 |
| Resistance Level | N/A | $44.89 |
| Average True Range (ATR) | 1.73 | 1.71 |
| MACD | 0.98 | 0.74 |
| Stochastic Oscillator | 99.44 | 97.89 |
ACI Worldwide Inc develops, markets, and installs a portfolio of software products focused on facilitating electronic payments. The firm's products are sold and supported directly and through distribution networks covering three geographic regions - the Americas, EMEA, and Asia Pacific. ACI software products process payment transactions for retail banking clients, billers such as utilities and healthcare providers, and community banks and credit unions. ACI's customers are financial institutions all over the world, but the majority of the revenue is generated in the United States and EMEA regions. The company's operating segment includes Payment Software and Biller. The company generates the majority of its revenue from the Payment Software segment.
Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.